NRx Pharmaceuticals (NASDAQ:NRXP) Releases Earnings Results, Misses Expectations By $0.10 EPS

NRx Pharmaceuticals (NASDAQ:NRXP) issued its quarterly earnings results on Friday. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10), Zacks reports.

NRx Pharmaceuticals Stock Up 13.5 %

Shares of NRXP traded up $0.28 during midday trading on Friday, reaching $2.35. 247,402 shares of the stock were exchanged, compared to its average volume of 448,145. The company has a market cap of $39.75 million, a price-to-earnings ratio of -1.10 and a beta of 1.22. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The firm has a 50 day simple moving average of $3.03 and a 200-day simple moving average of $2.02.

Wall Street Analyst Weigh In

A number of brokerages have commented on NRXP. D. Boral Capital restated a “buy” rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, January 28th. Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research note on Friday.

Insider Activity at NRx Pharmaceuticals

In related news, Chairman Jonathan C. Javitt purchased 40,000 shares of NRx Pharmaceuticals stock in a transaction on Tuesday, December 17th. The stock was bought at an average price of $1.17 per share, with a total value of $46,800.00. Following the completion of the transaction, the chairman now directly owns 84,634 shares of the company’s stock, valued at approximately $99,021.78. This represents a 89.62 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 19.00% of the stock is currently owned by company insiders.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.